PASTIC Dspace Repository

Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions

Show simple item record

dc.contributor.author Samad, Noreen
dc.contributor.author Yasmin, Farzana
dc.contributor.author Haleem, Darakhshan Jabeen
dc.date.accessioned 2022-10-07T10:22:44Z
dc.date.available 2022-10-07T10:22:44Z
dc.date.issued 2016-11-16
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/12785
dc.description.abstract Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia (TD). 0.2 mg/kg/rat dosage of haloperidol provided orally to rats for 2 weeks enhanced vacuous chewing movements that escalated when the process proceeded for 5 weeks. Following 2 weeks co-injection 5 mg/kg dosage of IMI was diminished haloperidol-instigated VCMs and fully averted following five weeks. The potency of 8-OH-DPATinstigated locomotor activity exhibited higher in saline+haloperidol treated rats while not observed in IMI+ haloperidol treated rats. 8-OH-DPAT-instigated low 5-hydroxytryptamine (5-HT; serotonin) metabolism was higher in saline+ haloperidol treated rats when compare to IMI+ haloperidol treated rats in both regions of brain (striatum and midbrain). It is recommended that IMI possibly competent in averting TD, in cases receiving treatment to antipsychotics. en_US
dc.language.iso en en_US
dc.publisher Karachi: Faculty of Pharmacy & Pharmaceutical Sciecnes, University of Karachi en_US
dc.subject Tardive dyskinesia en_US
dc.subject Imipramine en_US
dc.subject Haloperidol en_US
dc.subject Serotonin-1A receptor en_US
dc.title Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account